SOUTH SAN FRANCISCO, Calif., Feb. 2 /PRNewswire-FirstCall/ -- Exelixis, Inc. will release its fourth quarter and full year 2006 financial results on Tuesday, February 13, 2007 after the markets close. The announcement will be followed by a live webcast at 2:00 p.m. PT/5:00 p.m. ET of a discussion by Exelixis management of the fourth quarter and full year 2006 financial results and general business updates. The webcast may be accessed in the Event Calendar page under Investors at www.exelixis.com
An archive of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on March 15, 2007. Access numbers for this replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international); Passcode number is 31711445.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in Phase II and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Sankyo. For more information, please visit the company’s web site at www.exelixis.com
Exelixis, Inc.
CONTACT: Investor Contact, Charles Butler, Director, CorporateCommunications, Exelixis, Inc., +1-650-837-7277, cbutler@exelixis.com;Media Contact, Soleil Maxwell Harrison, Senior Manager, CorporateCommunications, Exelixis, Inc., +1-650-837-7012, sharrison@exelixis.com
